Cardiometabolic Risk in Patients with Classic Congenital Adrenal Hyperplasia
Overview
Classic congenital adrenal hyperplasia (CAH), primarily due to 21-hydroxylase deficiency, is associated with increased cardiometabolic risk including weight gain, insulin resistance, hypertension, endothelial dysfunction, and early atherosclerosis. These complications are more pronounced in classic CAH compared to nonclassic forms and are influenced by hormonal imbalances and treatment challenges.
Background
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterized by cortisol deficiency and compensatory ACTH elevation, leading to adrenal hyperplasia and androgen excess. The most common form, 21-hydroxylase deficiency, disrupts cortisol and aldosterone synthesis, resulting in classic (salt-wasting and simple virilizing) and nonclassic phenotypes. Treatment involves glucocorticoid replacement to suppress ACTH and androgen excess, but lifelong therapy carries risks of overtreatment and undertreatment. Cardiometabolic complications have emerged as significant concerns in CAH management.
Data Highlights
Studies report increased prevalence of weight gain, insulin resistance, hypertension, endothelial dysfunction, early atherosclerotic vascular changes, and left ventricular diastolic dysfunction in patients with classic CAH. These findings are less consistent in nonclassic CAH. The multifactorial etiology includes glucocorticoid overtreatment, imperfect hormone replacement, androgen excess, and adrenomedullary failure.
Key Findings
Classic CAH is associated with increased risk of weight gain and worsening insulin sensitivity.
Patients with classic CAH frequently exhibit high blood pressure and endothelial dysfunction.
Early atherosclerotic changes and left ventricular diastolic dysfunction have been documented in classic CAH.
Cardiometabolic complications are more consistently reported in classic CAH than in nonclassic CAH.
Excess cardiovascular morbidity is multifactorial, related to glucocorticoid overtreatment, androgen excess, and adrenal hormone replacement challenges.
New therapeutic approaches require targeted studies to evaluate their cardiometabolic effects.
Clinical Implications
Clinicians should monitor cardiometabolic risk factors closely in patients with classic CAH, balancing glucocorticoid dosing to avoid overtreatment while controlling androgen excess. Early identification and management of hypertension, insulin resistance, and vascular dysfunction are essential to reduce long-term cardiovascular morbidity. Personalized treatment strategies and further research into novel therapies are needed to optimize outcomes.
Conclusion
Classic CAH confers an increased cardiometabolic risk due to complex hormonal and treatment-related factors. Careful management and ongoing research are critical to mitigate cardiovascular and metabolic complications in this population.
References
Review Article 2024 -- Cardiometabolic Considerations in Patients with Congenital Adrenal Hyperplasia
